In contrast, in the SGLT2i-treated group, overall mortality risk was attenuated, and for many comorbidities the associations were weaker and did not reach statistical significance, highlighting the potential mitigating role of SGLT2i therapy. 4.
← all excerpts
Comorbidity patterns and mortality in HFpEF: A retrospective longitudinal cohort study.
1
—
—